EDGEMOND JAMES sold $110K of UTHR
EDGEMOND JAMES (CFO AND TREASURER) sold 200 shares of UNITED THERAPEUTICS Corp (UTHR) at $550.81 ($0.11M total) on 2026-06-01 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The disclosure provides a datapoint on insider liquidity but, due to the stated 10b5-1 pre-arranged plan, it is less likely to convey new fundamental information.
Market read
Routine insider selling under a pre-arranged plan; expect limited trading impact unless paired with other catalysts.
What to watch
Traders may over-weight single insider sales; the key check is whether there is a pattern of repeated sales or concurrent news (earnings, trial, guidance) not present here.
Background
The article is an SEC Form 4 insider transaction disclosure for United Therapeutics (UTHR).
Ticker impact
United Therapeutics CFO and treasurer Edgemond James sold $110K of UTHR shares via an open-market transaction under a 10b5-1 plan.
Limited near-term impact; any effect is likely small and sentiment-driven rather than fundamental.
The filing is a routine officer sale and explicitly tied to a pre-arranged 10b5-1 plan, reducing interpretive weight versus discretionary selling.
Market effects
Minimal; this is company-specific insider transaction with no stated sector-wide catalyst.
None indicated beyond routine US large-cap sentiment.
None indicated.
Counterpoint
Because the sale is under a 10b5-1 plan, it may reflect liquidity/compensation mechanics rather than bearish expectations; price impact could be negligible.
Key entities
- issuerUnited Therapeutics Corp
Subject of the SEC Form 4 insider sale disclosure.
- insiderEdgemond James
CFO and treasurer who sold 200 shares of UTHR for ~$110.2K under a 10b5-1 plan.
